Nutritional imperatives in cystic fibrosis therapy

Pediatric Annals

Volumn 28, Issue 2, 1999, Pages 129-136

  Erdman, Steven H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; RETINOL; TRIACYLGLYCEROL LIPASE; VITAMIN D; VITAMIN K GROUP;

CALORIC INTAKE; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALABSORPTION; MALNUTRITION; NUTRITIONAL STATUS; PHENOTYPE; QUALITY OF LIFE; REVIEW;

EID: 0033047502     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19990201-10     Document Type: Review

References (44)

1. Hanning RM, Blimkie DJK, Bar-Or O, Lands LC, Moss LA, Wilson WM. Relationships among nutritional status and skeletal and respiratory muscle function in cystic fibrosis: does early dietary supplementation make a difference? Am J Clin Nutr. 1993;57:580-587.
2. Dalzell AM, Shepherd RW, Dean B, Cleghorn GJ, Holt TL, Francis PJ. Nutritional rehabilitation in cystic fibrosis: a five year follow-up. J Pediatr Gastroenterol Nutr. 1992;15:141-145.
3. Cystic Fibrosis Foundation. Patient Registry: 1997 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 1998.
4. Kerem E, Reisman J, Corey M, Canny G, Levinson H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;32:1187-1191.
5. Durie PR. The pathophysiology of the pancreatic defect in cystic fibrosis. Acta Paed Scand. 1989;363(suppl):41-44.
6. Couper RT, Corey M, Moore DJ, et al. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res. 1992;32:179-182.
7. Campbell PW III, Phillips JA III. The cystic fibrosis gene and relationships to clinical status. Semin Respir Infect. 1992;7:150-157.
8. Guy-Crotte O, Carrere J, Figarella C. Exocrine pancreatic function in cystic fibrosis. Eur J Gastroenterol Hepatol. 1996;8:755-759.
9. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251-1254.
10. Atlas AB, Orenstein SR, Orenstein DM. Pancreatitis in young children with crystic fibrosis. J Pediatr. 1992;120:756-759. Erratum 1992;121:329.
11. Waters DL, Dorney SF, Gaskin KJ, et al. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med. 1990;322: 303-308.
12. Vaisman N, Pencharz PB, Corev M, Canny GI, Hahn E. Energy expenditure of patients with cystic fibrosis. J Pediatr. 1987;111:496-500.
13. Bronstein MN, Davies PS, Hambridge KM, Accurso FJ. Normal energy expenditure in the infant with presymptomatic cystic fibrosis. J Pediatr. 1995;126:28-33.
14. MacDonald A. Nutritional management of cystic fibrosis. Arch Dis Child. 1996;74:81-87.
15. Van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr. 1996;63:746-752.
16. Thompson GN. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1988;7:214-217.
17. Regan FT, Malagelada JR, Dimagno EP, Go VL. Reduced intraluminal bile acid concentrations and fat maldigestion in pancreatic insufficiency: correction by treatment. Gastroenterology. 1979;77:285-289.
18. Smith LJ, Lacille F, Lepage G, et al. Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. American Journal of Diseases in Children. 1991;145: 1401-1404.
19. Duggan C, Colin AA, Agil A, et al. Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr. 1996;64:635-639.
20. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child. 1995;72: 281-284.
21. Laughlin JJ, Brady MS, Eigen H. Changing feeding trends as a cause of electrolyte depletion in infants with cystic fibrosis. Pediatrics. 1981;68:203-207.
22. Durie PR, Newth CJ, Forstner GG, Gall DG. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzymes supplements. J Pediatr. 1980;96:862-864.
23. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr. 1994; 83:849-853.
24. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in CF: a consensus report. Am J Clin Nutr. 1992;55:108-116.
25. Thomson MA, Bucolo S, Quirk P, Shepherd RW. Measured versus predicted resting energy expenditure in infants: a need for reappraisal. J Pediatr. 1995;126:21-27.
26. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41:583-591.
27. Kane RE, Hobbs P. Energy and respiratory metabolism in cystic fibrosis: the influence of carbohydrate content of nutritional supplements. J Pediatr Gastroenterol Nutr. 1991;12:217-223.
28. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981;34:2540-2545.
29. Nir M, Lanng S, Johansen HK, Koch C. Long term survival and nutritional data in patients with cystic fibrosis treated in a Danish center. Thorax. 1996;51:1023-1027.
30. Levy LD, Durie PR, Pencharz PB, Corey ML. Effects of long term nutritional rehabilitation on body composition and clinical status in malnourished children and adolescents with cystic fibrosis. J Pediatr. 1985;107:225-230.
31. Shepherd RW, Holt TL, Thomas BJ, et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of the effects on nutritional growth retardation body protein turnover and course of pulmonary disease. J Pediatr. 1986;109:788-794.
32. Steinkamp G, von der Hardt H. Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feeding in cystic fibrosis. J Pediatr. 1994; 124:244-249.
33. Murphy JL, Wootton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients with cystic fibrosis. Arch Dis Child. 1991;66: 495-500.
34. Vyas H, Matthew DJ, Milla PJ. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis: a controlled study. Eur J Pediatr. 1990;149:241-243.
35. Lloyd DR, Rawahsdeh MO, Booth IW, Brown GA. The steatocrit: an improved procedure. Ann Clin Biochem. 1992;29:535-540.
36. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127:681-684.
37. Lebenthal E. High strength pancreatic exocrine enzyme capsules associated with colonic strictures in patients with cystic fibrosis: "more is not necessarily better." J Pediatr Gastroenterol Nutr. 1994;18:423-425. Editorial.
38. FitzSimmons SC, Burkhart GA, Borowitz D. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336:1283-1289.
39. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166-174.
40. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology. 1996;23:1484-1490.
41. Thomas PS, Bellamy M, Geddes D. Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid. Lancet. 1995;346:1230-1231. Letter.
42. Lepage G, Paradis K, Lacaille R, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr. 1997;130:52-58.
43. Taurine supplementation in cystic fibrosis. Nutr Rev. 1988;46:257-258.
44. Belli DC, Levy E, Darling P, et al. Taurine improves the absorption of a fat meal in patients with cystic fibrosis. Pediatrics. 1987;80:517-523.